Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
Wednesday, October 8, 2025 2 min read
Key Takeaway: Penumbra, Inc. will host an investor event on October 26, 2025, at the TCT Conference, focusing on the STORM-PE clinical trial. A conference call for third quarter financial results is scheduled for November 5, 2025. The events will be accessible via webcast, emphasizing the company's commitment to transparency and investor engagement.
Price reaction · baseline $258.95 (2025-10-08 close) · hit after-hours · clean, no other PEN news in the window
day 0 close · peak
+0.9%
Market Sentiment Analysis
POSITIVE FACTORS
Penumbra is hosting an investor event at a major conference.
The STORM-PE clinical trial will be discussed, showcasing innovation.
The company is committed to improving patient outcomes globally.
Full Press Release Details
ALAMEDA, Calif.,Oct. 8, 2025/PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference. Management and members of the STORM-PE steering committee will discuss the Company's STORM-PE clinical trial followed by a question-and-answer session. A live webcast of the event can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website atwww.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the event.
The Company also announced that it will host a conference call to discuss financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025 at 4:30 PM Eastern Time. A press release with third quarter 2025 financial results will be issued after market close that day. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website atwww.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visitwww.penumbrainc.comand connect onInstagram,LinkedInandX.
Investor RelationsPenumbra, Inc.[email protected]
Frequently Asked Questions
When is Penumbra's investor event scheduled?
The investor event is scheduled for October 26, 2025.
What will be discussed at the investor event?
The STORM-PE clinical trial will be discussed during the event.
How can I access the investor event?
The event will be available via live webcast on Penumbra's website.
When will the Q3 earnings call take place?
The Q3 earnings call is scheduled for November 5, 2025.
What is Penumbra known for?
Penumbra is a leading thrombectomy company focused on innovative medical technologies.